

Testing for COVID-19

Date Thursday 4 June 12.30pm
Presenters Mr Robert Skeen
Prof Dominic Dwyer
Ms Ruth Luppino



This activity has been developed in partnership with Aboriginal Health & Medical Research Council of NSW and NSW Health



Healthy Profession.
Healthy Australia.

Acknowledgement of Country

We recognise the traditional custodians of the land and sea on which we live and work.

We pay our respects to Elders past and present.



Healthy Profession.
Healthy Australia.

Learning Outcomes

By the end of this webinar, participants will:

- Understand the importance of testing for COVID-19
- Understand the role of different types of testing in the diagnosis and management of cases with COVID-19
- Understand how to access testing and support for test interpretation



Healthy Profession.
Healthy Australia.

Presenters



Robert Skeen
CEO, AH&MRC



Professor Dominic Dwyer
Director of Public Health Pathology, New South Wales Health Pathology



Ruth Luppino
Practice Manager at Coonamble Aboriginal Health Service



Healthy Profession.
Healthy Australia.

Robert Skeen


WELCOME & UPDATE



Healthy Profession.
Healthy Australia.

Current Situation in NSW

- 30 cases = 1% of all cases in NSW
- No deaths
- Comparable rates of testing



*Total rates include people with unknown Aboriginality status.



Healthy Profession.
Healthy Australia.

Testing criteria is now symptom based


Test everyone with:

- Respiratory symptoms OR
- Unexplained fever



Healthy Profession.
Healthy Australia.

High testing rates in NSW are needed as restrictions ease



Healthy Profession.
Healthy Australia.


Supporting Community Testing

Barriers include:

- Access to transport
- Limited hours at GP Respiratory clinics
- Long distances for regional members

Time to Nearest Testing Site

Region ● Metropolitan ● Northern ● Southern ● Western



Healthy Profession.
Healthy Australia.

Dominic Dwyer

TESTING FOR COVID-19



Healthy Profession.
Healthy Australia.

A new coronavirus (SARS-CoV-2) causing a new illness (COVID-19)

Not secure | virological.org/t/novel-2019-coronavirus-genome/319



Novel 2019 coronavirus genome

Novel 2019 coronavirus



edward_holmes

6 Jan 10

10th January 2020


This posting is communicated by Edward C. Holmes, University of Sydney on behalf of the consortium led by Professor Yong-Zhen Zhang, Fudan University, Shanghai



Royal Australian College of General Practitioners

rofession
ustralia.

Interventions to slow disease spread



Adapted from CDC / The Economist

Laboratory tests for COVID-19 disease

- Nucleic acid testing
- Serology
- Virus isolation (or virus culture)
- Whole genome sequencing (WGS)
- Tests for disease management



Healthy Profession.
Healthy Australia.

Developing SARS-CoV-2 nucleic acid detection tests




Figure 1 relative positions of amplicon targets on SARS-CoV and Wuhan-CoV genome. N: nucleocapsid; ORF: open reading frame; RdRp: RNA-dependent RNA polymerase. Numbers below amplicon are genome positions according to SARS-CoV, NC_004718.

Nucleic acid testing for COVID-19 disease

- 'NAT' or 'PCR' or 'molecular tests'
- Multiple high throughput platforms
- Turnaround times vary and depend on the definition
 - Clinical TATs ~12-40 hours
 - In-laboratory TATs ~6 hours
- Rapid individual PCR tests eg Genexpert
 - <1 hour in-lab



Healthy Profession.
Healthy Australia.

Nucleic acid testing for COVID-19 disease


- Issues around sensitivity and specificity
- Variation between platforms
- Sample collection
 - Methods of swabbing the upper respiratory tract
 - Swab types
 - Transport media
- Reagent shortages
- Clinical indications for testing



Healthy Profession.
Healthy Australia.

40,000 tests in NSW Health Pathology later..

Figure 1 Cycle threshold values of clinical samples (O), cell culture supernatant (■) and synthetic positive controls (X) for nucleic acid test assays targeting different regions of the SARS-CoV-2 genome



Healthy Profession.
Healthy Australia.

Virus isolation or culture


- Risk group 3 pathogen
 - Cultures performed in PC3/4 laboratory
- Use cell lines - Vero-E6 cells
- Observe for cytopathic effect (CPE) and confirm by PCR
- Studies in persistently NAT positive patients, including in healthcare workers



Healthy Profession.
Healthy Australia.



Electron microscopy of SARS-CoV-2



RACGP

Royal Australian College of General Practitioners

ER-20-131 CMDLS_K_022_IB1 INFECTED.tif
IB1 INFECTED
16:28 3/19/2020
TEM Mode: Imaging
Microscope: LN

200 nm
HV=80kV
Direct Mag: 70000 x
ICPMR WESTMEAD

Healthy Profession.
Healthy Australia.

PCR positivity vs culture positivity



Healthy Profession.
Healthy Australia.

Indications for serology (SARS-CoV-2 antibodies)

- Making a **retrospective diagnosis** in individuals who have recovered from infection prior to testing
- Identifying cases where **false negative nucleic acid testing** has occurred, either because of sampling issues or mutations at primer/probe binding sites
- Confirmation of **unexpected positive nucleic acid tests**: especially important in settings of low incidence
- Identifying **asymptomatic infection**, especially in close contacts of cases or healthcare workers
- Determining the extent of infection in a population through **serosurveys**




Healthy Profession.
Healthy Australia.

SARS-CoV-2 serology at NSWHP–ICPMR Westmead

- First results 20th February using immunofluorescence (IFA)
- SARS-CoV-2-specific IgG, IgM and IgA
- IgG is a marker of past infection; IgM and IgA are markers of more recent infection
- Virus neutralisation is available as another specific test for SARS-CoV-2-specific antibody



Healthy Profession.
Healthy Australia.



SARS-CoV-2 infected cells
showing cytoplasmic
immunofluorescent
staining

Healthy Profession.
Healthy Australia.

Courtesy of Linda Hueston, ICPMR

SARS-CoV-2 serology at NSWHP–ICPMR, Westmead

- >6500 samples tested
 - Routine diagnosis
 - Outbreak investigations (schools, ACFs, Ruby Princess crew)
 - Population serosurveys
- Evaluations of commercial platforms
 - Point-of-care antibody tests
 - Euroimmun ELISA, Abbott Architect CMIA....
- In-house EIA in development




Healthy Profession.
Healthy Australia.

Kinetics of the SARS-CoV-2 antibody response



Healthy Profession.
Healthy Australia.

Detection of SARS-CoV-2 antibodies at different times after onset of illness



RAPID COMMUNICATION

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020

Kenji Mizumoto^{1,2,7}, Katsushi Kagaya^{3,4}, Alexander Zarebski⁵, Gerardo Chowell³

1. Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University Yoshida-Nakaadachi-cho, Sakyo-ku, Kyoto, Japan
2. Hakubi Center for Advanced Research, Kyoto University, Yoshidahonmachi, Sakyo-ku, Kyoto, Japan
3. Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, Georgia, United States
4. Seto Marine Biological Laboratory, Field Science, Education and Research Center, Kyoto University, Shirahama-cho, Nishimuro-gun, Wakayama, Japan
5. Department of Zoology, University of Oxford, Oxford, United Kingdom

Correspondence: Kenji Mizumoto (mizumoto.kenji.sa@kyoto-u.ac.jp)


Citation style for this article:
Mizumoto Kenji, Kagaya Katsushi
cases on board the Diamond Princess
ES.2020.25.10.2000180

The estimated asymptomatic
proportion was
17.9%
95% credible interval:15.5–20.2%

2020 (COVID-19)
807/1560-7917.

/ published on 12 Mar 2020

Whole Genome Sequencing – infection clusters in NSW



Healthy Profession.
Healthy Australia.

Sintchenko V et al. WGS SitRep 29/05/20



Coronavirus Disease 2019 (COVID-19) CDNA National Guidelines for Public Health Units

<https://www1.health.gov.au/internet/main/publishing.nsf/Content/cdna-song-novel-coronavirus.htm>

Confirmed case

A person who:

- I. tests positive to a validated specific SARS-CoV-2 nucleic acid test;
OR
- II. has the virus isolated in cell culture, with PCR confirmation using a validated method;
OR
- III. undergoes a seroconversion to or has a significant rise in SARS-CoV-2 neutralising or IgG antibody level (e.g. four-fold or greater rise in titre).¹

Probable case

A person who:

- I. has not been tested, with fever ($\geq 38^{\circ}\text{C}$)² or history of fever (e.g. night sweats, chills) **OR** acute respiratory infection (e.g. cough, shortness of breath, sore throat) **AND** is a household contact (refer to [Contact definition](#) below) of a confirmed or probable³ case of COVID-19;
OR
- II. has detection of SARS-CoV-2 neutralising or IgG antibody³ **AND** has had a compatible clinical illness **AND** is a close contact (refer to [Contact definition](#) below) of a confirmed or probable³ case of COVID-19.



Healthy Profession.
Healthy Australia.

Ruth Luppino



COONAMBLE'S EXPERIENCE



Healthy Profession.
Healthy Australia.

Useful resources

- NSW Health Website – Testing Advice for General Practitioners
<https://www.health.nsw.gov.au/Infectious/covid-19/Pages/case-definition.aspx>
- NSW Health Website – Advice for ACCHSs
<https://www.health.nsw.gov.au/Infectious/covid-19/Pages/aboriginal-services.aspx>
- AH&MRC Website
<https://www.ahmrc.org.au/coronavirus/>



Healthy Profession.
Healthy Australia.

Any questions....

Thank you



Healthy Profession.
Healthy Australia.